Confirmed
One controlled phase 3 trial met its main goal, and teriflunomide is approved for this use.
DHODH inhibition (pyrimidine synthesis): reduce relapses and new lesions in early MS (CIS or RIS)
early MS (CIS or RIS) · DHODH inhibition (pyrimidine synthesis)
Two or more controlled phase 3 trials met their main goal, or one did and a medicine of this approach is approved for this use.
- Trials
- 1
- Running now
- 0
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 618
Deciding trials (phase 3): 1 met, 0 did not.
Other linked trials: 0
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Phase 3 · 2008 · Placebo-controlled · MSFT-NCT00622700
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-27First listed as Confirmed
Related hypotheses
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error